Which has preferable earnings and valuation, HELP or OGN?

Organon & Co. has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$148M -$3.02 N/A Organon & Co. $6.13B 0.59 $187M $0.77 17.76

Is HELP or OGN more profitable?

Organon & Co. has a net margin of 3.41% compared to Cybin's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% Organon & Co. 3.41% 88.97% 6.03%

Does the media favor HELP or OGN?

In the previous week, Cybin had 17 more articles in the media than Organon & Co.. MarketBeat recorded 24 mentions for Cybin and 7 mentions for Organon & Co.. Cybin's average media sentiment score of 1.53 beat Organon & Co.'s score of 1.34 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Organon & Co. 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer HELP or RGC?

Cybin presently has a consensus target price of $48.60, indicating a potential upside of 270.43%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, HELP or RGC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$148M -$3.02 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is HELP or RGC more profitable?

Regencell Bioscience's return on equity of 0.00% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% Regencell Bioscience N/A N/A N/A

Which has better earnings and valuation, HELP or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$148M -$3.02 N/A Structure Therapeutics N/A N/A -$141.20M -$1.00 N/A

Is HELP or GPCR more profitable?

Structure Therapeutics' return on equity of -25.56% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% Structure Therapeutics N/A -25.56% -24.31%

Does the media favor HELP or GPCR?

In the previous week, Cybin had 14 more articles in the media than Structure Therapeutics. MarketBeat recorded 24 mentions for Cybin and 10 mentions for Structure Therapeutics. Cybin's average media sentiment score of 1.53 beat Structure Therapeutics' score of 0.72 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Structure Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARQT or HELP?

In the previous week, Cybin had 19 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 24 mentions for Cybin and 5 mentions for Arcutis Biotherapeutics. Cybin's average media sentiment score of 1.53 beat Arcutis Biotherapeutics' score of 1.08 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, HELP or MBX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$148M -$3.02 N/A MBX Biosciences N/A N/A -$86.97M -$2.41 N/A

Is HELP or MBX more profitable?

MBX Biosciences' return on equity of -26.02% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% MBX Biosciences N/A -26.02% -24.94%

Does the media favor HELP or MBX?

In the previous week, Cybin had 22 more articles in the media than MBX Biosciences. MarketBeat recorded 24 mentions for Cybin and 2 mentions for MBX Biosciences. Cybin's average media sentiment score of 1.53 beat MBX Biosciences' score of 0.92 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cybin (HELP) Competitors

$13.12 -0.49 (-3.60%)

Closing price 04:00 PM Eastern

Extended Trading

$13.41 +0.29 (+2.21%)

As of 04:24 PM Eastern

Compare

HELP vs. OGN, RGC, GPCR, ARQT, and MBX

Should you buy Cybin stock or one of its competitors? Cybin's main competitors and comparable companies include Organon & Co. (OGN), Regencell Bioscience (RGC), Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), and MBX Biosciences (MBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cybin compare to Organon & Co.?

Cybin (NASDAQ:HELP) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

17.9% of Cybin shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Organon & Co. has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Organon & Co.	$6.13B	0.59	$187M	$0.77	17.76

Cybin presently has a consensus price target of $48.60, indicating a potential upside of 270.43%. Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 16.64%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Organon & Co. has a net margin of 3.41% compared to Cybin's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Organon & Co.	3.41%	88.97%	6.03%

In the previous week, Cybin had 17 more articles in the media than Organon & Co.. MarketBeat recorded 24 mentions for Cybin and 7 mentions for Organon & Co.. Cybin's average media sentiment score of 1.53 beat Organon & Co.'s score of 1.34 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Organon & Co.	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cybin has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Summary

Organon & Co. beats Cybin on 9 of the 15 factors compared between the two stocks.

How does Cybin compare to Regencell Bioscience?

Cybin (NASDAQ:HELP) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Regencell Bioscience's return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Regencell Bioscience	N/A	N/A	N/A

In the previous week, Cybin had 23 more articles in the media than Regencell Bioscience. MarketBeat recorded 24 mentions for Cybin and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.87 beat Cybin's score of 1.53 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Cybin	Very Positive
Regencell Bioscience	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

17.9% of Cybin shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cybin has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Cybin presently has a consensus target price of $48.60, indicating a potential upside of 270.43%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cybin beats Regencell Bioscience on 6 of the 11 factors compared between the two stocks.

How does Cybin compare to Structure Therapeutics?

Cybin (NASDAQ:HELP) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Cybin currently has a consensus price target of $48.60, indicating a potential upside of 270.43%. Structure Therapeutics has a consensus price target of $110.91, indicating a potential upside of 184.75%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

Structure Therapeutics' return on equity of -25.56% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Structure Therapeutics	N/A	-25.56%	-24.31%

In the previous week, Cybin had 14 more articles in the media than Structure Therapeutics. MarketBeat recorded 24 mentions for Cybin and 10 mentions for Structure Therapeutics. Cybin's average media sentiment score of 1.53 beat Structure Therapeutics' score of 0.72 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Structure Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

17.9% of Cybin shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cybin has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.45, indicating that its share price is 245% less volatile than the broader market.

Summary

Cybin and Structure Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Cybin compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Cybin's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Cybin	N/A	-71.78%	-64.81%

In the previous week, Cybin had 19 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 24 mentions for Cybin and 5 mentions for Arcutis Biotherapeutics. Cybin's average media sentiment score of 1.53 beat Arcutis Biotherapeutics' score of 1.08 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Arcutis Biotherapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Cybin has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

17.9% of Cybin shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$463.98M	6.37	-$16.14M	$0.21	111.95
Cybin	N/A	N/A	-$148M	-$3.02	N/A

Arcutis Biotherapeutics currently has a consensus price target of $35.57, indicating a potential upside of 51.30%. Cybin has a consensus price target of $48.60, indicating a potential upside of 270.43%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Arcutis Biotherapeutics beats Cybin on 9 of the 15 factors compared between the two stocks.

How does Cybin compare to MBX Biosciences?

Cybin (NASDAQ:HELP) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

MBX Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

17.9% of Cybin shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 31.1% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cybin has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

In the previous week, Cybin had 22 more articles in the media than MBX Biosciences. MarketBeat recorded 24 mentions for Cybin and 2 mentions for MBX Biosciences. Cybin's average media sentiment score of 1.53 beat MBX Biosciences' score of 0.92 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MBX Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cybin presently has a consensus target price of $48.60, indicating a potential upside of 270.43%. MBX Biosciences has a consensus target price of $77.00, indicating a potential upside of 26.06%. Given Cybin's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cybin is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

MBX Biosciences' return on equity of -26.02% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
MBX Biosciences	N/A	-26.02%	-24.94%

Summary

Cybin and MBX Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HELP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HELP vs. The Competition

Export

Metric	Cybin	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$992.00M	$12.44B	$7.16B	$14.34B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-4.34	792.10	273.41	25.32
Price / Sales	N/A	763.25	674.51	98.42
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	2.92	10.40	10.38	6.20
Net Income	-$148M	$2.83B	$3.49B	$358.18M
7 Day Performance	5.89%	-3.28%	-2.17%	-1.58%
1 Month Performance	9.42%	0.80%	-0.37%	-3.60%
1 Year Performance	N/A	3.62%	19.18%	5.95%

Cybin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HELP Cybin	4.6166 of 5 stars	$13.12 -3.6%	$48.60 +270.4%	N/A	$992.00M	N/A	N/A	100	Positive News
OGN Organon & Co.	1.5911 of 5 stars	$13.77 -0.1%	$11.40 -17.2%	+28.1%	$3.62B	$6.13B	17.88	10,000	Positive News
RGC Regencell Bioscience	0.4694 of 5 stars	$6.82 -1.0%	N/A	-61.0%	$3.41B	N/A	N/A	10
GPCR Structure Therapeutics	2.8567 of 5 stars	$40.38 -14.7%	$110.91 +174.7%	+83.8%	$3.30B	N/A	N/A	136	High Trading Volume
ARQT Arcutis Biotherapeutics	3.8812 of 5 stars	$24.39 +2.1%	$35.57 +45.8%	+40.4%	$3.00B	$463.98M	116.15	150	Positive News Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HELP) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cybin (HELP) Competitors

HELP vs. OGN, RGC, GPCR, ARQT, and MBX

How does Cybin compare to Organon & Co.?

Summary

How does Cybin compare to Regencell Bioscience?

Summary

How does Cybin compare to Structure Therapeutics?

Summary

How does Cybin compare to Arcutis Biotherapeutics?

Summary

How does Cybin compare to MBX Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cybin (HELP) Competitors

HELP vs. OGN, RGC, GPCR, ARQT, and MBX

How does Cybin compare to Organon & Co.?

Do insiders & institutionals have more ownership in HELP or OGN?

Which has preferable earnings and valuation, HELP or OGN?

Do analysts rate HELP or OGN?

Is HELP or OGN more profitable?

Does the media favor HELP or OGN?

Which has more risk & volatility, HELP or OGN?

Summary

How does Cybin compare to Regencell Bioscience?

Is HELP or RGC more profitable?

Does the media favor HELP or RGC?

Which has preferable valuation & earnings, HELP or RGC?

Do insiders and institutionals believe in HELP or RGC?

Which has more volatility and risk, HELP or RGC?

Do analysts prefer HELP or RGC?

Summary

How does Cybin compare to Structure Therapeutics?

Do analysts prefer HELP or GPCR?

Is HELP or GPCR more profitable?

Does the media favor HELP or GPCR?

Which has better earnings and valuation, HELP or GPCR?

Do institutionals & insiders believe in HELP or GPCR?

Which has more volatility & risk, HELP or GPCR?

Summary

How does Cybin compare to Arcutis Biotherapeutics?

Is ARQT or HELP more profitable?

Does the media refer more to ARQT or HELP?

Which has more volatility and risk, ARQT or HELP?

Do insiders and institutionals have more ownership in ARQT or HELP?

Which has preferable earnings & valuation, ARQT or HELP?

Do analysts prefer ARQT or HELP?

Summary

How does Cybin compare to MBX Biosciences?

Which has preferable valuation and earnings, HELP or MBX?

Do insiders & institutionals believe in HELP or MBX?

Which has more volatility and risk, HELP or MBX?

Does the media favor HELP or MBX?

Do analysts recommend HELP or MBX?

Is HELP or MBX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools